STRATEGIC MARKET ACCESS PLANNING IN BREAST AND LUNG CANCER ENABLED BYREAL-TIMEAI-ASSISTEDLIVINGSYSTEMATICLITERATUREREVIEW (REAL-SLR)SYSTEM
Author(s)
Stacy Grieve, PhD1, Sherrie Schreiber-Gosche, MSc1, Stefan Walzer, MA, PhD2, Rozee Liu, MSc1, Anna Forsythe, MBA, MSc, PharmD1;
1Oncoscope-AI, Miami, FL, USA, 2MArS Market Access & Pricing Strategy GmbH, Weil am Rhein, Germany
1Oncoscope-AI, Miami, FL, USA, 2MArS Market Access & Pricing Strategy GmbH, Weil am Rhein, Germany
OBJECTIVES: In cancers characterized by rapid evidence generation, such as breast or lung cancer, market access strategies require continuous monitoring of evolving comparator landscapes, endpoints, and subpopulations to meet the needs of heterogeneous payer and health technology assessment (HTA) requirements. This study evaluates the use of a REAL-SLR system to support strategic market access planning in breast and non-small cell lung cancer (NSCLC), comparing to traditional static SLR approaches.
METHODS: REAL-SLRs were implemented using protocol-driven, PRISMA-aligned searches for breast and NSCLC with updates performed daily. Evidence from interventional trials, selected high-quality real-world evidence (RWE), regulatory approvals, clinical guidelines, and HTA reviews were systematically identified and structured in real-time. Outputs were aligned to market access needs including evolving comparator standards, biomarker-defined subpopulations, payer-relevant endpoints, and quality-of-life (QoL) measures. Evidence was continuously mapped to regulatory and HTA milestones to support early pipeline planning, value story development, pricing and reimbursement strategy, and parallel regulatory-HTA preparation.
RESULTS: Across breast cancer, the REAL-SLR captured 923 interventional trials, 5 guideline updates, 60 distinct clinical endpoints, and 26 QoL instruments, alongside 25 HTA reviews from major agencies. In NSCLC, the system tracked 1526 interventional trials, 11 guideline updates, 89 endpoints, 20 biomarker-defined subpopulations, 23 QoL scales, and 106 HTA reviews. Compared with static SLRs, the living approach enabled identification of changes in relevant measures 6-12 months earlier, reduced time to incorporate late-breaking conference data by 75% and eliminated the need for 3-5 updates of custom SLRs over the development lifecycle. Strategic teams used the living evidence base to test alternative positioning scenarios, anticipate payer objections, and identify evidence gaps 6-12 months earlier than with traditional approaches.
CONCLUSIONS: A REAL-SLR system provides a foundation for strategic market access planning by transforming evidence synthesis into a continuously updated capability. This approach improves agility, reduces duplication, and supports consistent, payer-relevant value narratives.
METHODS: REAL-SLRs were implemented using protocol-driven, PRISMA-aligned searches for breast and NSCLC with updates performed daily. Evidence from interventional trials, selected high-quality real-world evidence (RWE), regulatory approvals, clinical guidelines, and HTA reviews were systematically identified and structured in real-time. Outputs were aligned to market access needs including evolving comparator standards, biomarker-defined subpopulations, payer-relevant endpoints, and quality-of-life (QoL) measures. Evidence was continuously mapped to regulatory and HTA milestones to support early pipeline planning, value story development, pricing and reimbursement strategy, and parallel regulatory-HTA preparation.
RESULTS: Across breast cancer, the REAL-SLR captured 923 interventional trials, 5 guideline updates, 60 distinct clinical endpoints, and 26 QoL instruments, alongside 25 HTA reviews from major agencies. In NSCLC, the system tracked 1526 interventional trials, 11 guideline updates, 89 endpoints, 20 biomarker-defined subpopulations, 23 QoL scales, and 106 HTA reviews. Compared with static SLRs, the living approach enabled identification of changes in relevant measures 6-12 months earlier, reduced time to incorporate late-breaking conference data by 75% and eliminated the need for 3-5 updates of custom SLRs over the development lifecycle. Strategic teams used the living evidence base to test alternative positioning scenarios, anticipate payer objections, and identify evidence gaps 6-12 months earlier than with traditional approaches.
CONCLUSIONS: A REAL-SLR system provides a foundation for strategic market access planning by transforming evidence synthesis into a continuously updated capability. This approach improves agility, reduces duplication, and supports consistent, payer-relevant value narratives.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
HTA43
Topic
Health Technology Assessment
Topic Subcategory
Decision & Deliberative Processes
Disease
SDC: Oncology, SDC: Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory)